pCDCAR1EGFR h(4ζ), T(CAR-T-2-L338-4Z)
The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to a CD4 transmembrane domain and CD3-zeta signaling domains. And the vector product was designed for the immune response cells in preparation of drugs for treatment of malignant tumor and virus infected diseases.
Details
Targeting Cell Type
T cell
Targeting Diseases
Melanoma
Receptor Construction
scFv-CD4-CD3ζ
Discription of Signaling Cassetes
CD4
Cluster of Differentiation 4 (CD4) is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages and dendritic cells, and plays an important role in the development and activation of T cells. On T cells, CD4 is the co-receptor for the T cell receptor (TCR), and these two distinct structures recognize the Antigen-Major Histocompatibility Complex (MHC). CD4 signaling in CAR ensures specificity of the TCR-antigen interaction, prolongs the contact between the T cell and the antigen presenting cell and recruits the tyrosine kinase Lck, which is essential for T cell activation.
CD3ζ
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
Target
Gene Name
Epidermal growth factor receptor
Synonyms
ERBB; HER1; mENA; ERBB1; PIG61; NISBD2
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
| Cat# |
Description |
| CAR-MZ083 |
Anti-EGFRvIII (131) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 |
| OAdCmodV-YX0634 |
Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/55k, Anti-EGFR-9), Viral particle |
| CAR-LC377 |
Anti-EGFR h(CD28-CD3ζ, GITR) Armoured CAR, pCDCAR1 |
| CAR-MZ010 |
Anti-EGFR (Nimotuzumab) h(CD28-CD3ζ) CAR, pCDCAR1 |
| OAdCmodV-YX0665 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ24/19k, Anti-EGFR-4), Viral particle |
| OAdCmodV-YX0603 |
Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ55k, Anti-EGFR-2), Viral particle |
| OAdCmodV-YX0658 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ55k, Anti-EGFR-9), Viral particle |
| OAdCmodV-YX0675 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ24/55k, Anti-EGFR-2), Viral particle |
| OAdCmodV-YX0672 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ24/19k, Anti-EGFR-11), Viral particle |
| OAdCmodV-YX0683 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ24/55k, Anti-EGFR-10), Viral particle |
BlastomaOncolytic VirusCarcinoma
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: